Download PDF
Thromb Haemost 1968; 20(01/02): 234-246
DOI: 10.1055/s-0038-1651263
Originalarbeiten – Original Articles – Travaux Originaux
Schattauer GmbH

On the Nature of Antithrombin V

H Vinazzer
1   Blood Coagulation Laboratory Dr. Vinazzer (Head: Dr. H. Vinazzer), Linz (Austria)
,
F Reinhardt
2   Medical Department, Hospital of the Barmherzigen Brüder (Head: Doz. Dr. F. Reinhardt), Linz (Austria)
› Author Affiliations
Further Information

Publication History

Publication Date:
27 June 2018 (online)

  PDF Download  Permissions and Reprints

Summary

Two cases of myeloma with a severe bleeding tendency due to the occurrence of antithrombin V could be observed. The following data on this inhibitor were collected:

1. The inhibitor activity could be temporarily suppressed by long term treatment with cortisone. The long lag period indicates that a cellular function must be responsible for the production of antithrombin V.

2. Various tests confirmed that antithrombin V is a true inhibitor of thrombin and not a polymerization inhibitor.

3. The esterase activity of thrombin is not inhibited by antithrombin V.

4. The reptilase activity is reduced by antithrombin V.

5. Highly concentrated antithrombin V could be extracted from a patient’s bone marrow. This led to the assumption that the bone marrow participates in the production of antithrombin V.

6. Sephadex fractionation of the serum revealed that the entire antithrombin V activity moves with the A-fraction.

7. On ultrafiltration, the antithrombin activity remained on the diaphragm, indicating that antithrombin V is a true protein and not a split product.

 

  • References

  • 1 Chambers R, Zweifach W.B. Intracellular cement and capillary permeability. Physiol. Rev 1947; 27: 436
    CrossrefPubMedGoogle Scholar
  • 2 Craddock G.C, Adams W.S, Figueroa W.G. Interference with fibrin formation in multiple myeloma by an unusual protein found in blood and urine. J. Lab. clin. Med 1953; 42: 844
    PubMedGoogle Scholar
  • 3 Frick P.G. Inhibition of conversion of fibrinogen to fibrin by abnormal proteins in multiple myeloma. Amer. J. clin. Path 1955; 25: 1263
    PubMedGoogle Scholar
  • 4 Frick P.G. Les inhibiteurs de la phase terminale de la coagulation. Sang 1959; 30: 405
    PubMedGoogle Scholar
  • 5 Göttinger E, Vinazzer H. Der Einfluß von ÄDTA auf die Blutgerinnung. Thrombos. Diathes. haemorrh. (Stuttg.) 1964; 11: 513
    PubMedGoogle Scholar
  • 6 Jürgens J, Beller F.K. Klinische Methoden der Blutgerinnungsanalyse. Thieme; Stuttgart: 1959: S285
    Google Scholar
  • 7 Kautsch F. Störungen der Blutgerinnung beim Plasmocytom. Klin. Wschr 1957; 35: 77
    CrossrefPubMedGoogle Scholar
  • 8 Loeliger E.A, Hers J.F. Chronic antithrombinemia (antithrombin V) with hemorrhagic diathesis in a case of rheumatoid arthritis with hypergammaglobulinemia. Thrombos. Diathes. haemorrh. (Stuttg.) 1957; 1: 499
    PubMedGoogle Scholar
  • 9 Markwardt F. Der Einfluß der Thrombininhibitoren auf Nebenwirkungen des Thrombins. Thrombos. Diathes. haemorrh. (Stuttg.) 1961; 5: 576
    PubMedGoogle Scholar
  • 10 Reinhardt F, Vinazzer H. Gerinnungssysteme im Latexmilieu.(In press.).
    PubMed
  • 11 Sigg P. The monoiodacetate tolerance test as a new quantitative method for thefibrin stabilizing factor assay. Thrombos. Diathes. haemorrh. (Stuttg.) 1966; 15: 238
    PubMedGoogle Scholar
  • 12 Struzik T, Hanicki Z, Hawiger J. Cryocoagulopathy with presence of immunoantithrombin in the course of L. E. disseminatus. Acta med. pol 1964; 5: 61
    PubMedGoogle Scholar
  • 13 Vermylen C, Verstraete M. Antithrombin V: Critical evaluation of its assessment and properties. Thrombos. Diathes. haemorrh. (Stuttg.) 1961; 5: 267
    PubMedGoogle Scholar